BATTLE TESTED
IN EOS DISEASE

NUCALA—the only FDA-approved therapy
for EGPA—offered patients more time in
remission and a lower daily OCS dose

NUCALA—the only FDA-approved therapy for EGPA—offered patients more time in remission and a lower daily OCS dose

NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Choose NUCALA for EGPA

Increased time in remission

2.8x

Red calendar icon

as many patients
achieved remission1*

NUCALA, 53% (n=36/68)
vs placebo, 19% (n=13/68)

Subanalysis. Results are descriptive.

Reduced daily OCS dose

1in5

Two pills icon

patients ELIMINATED daily steroids
in the last 4 weeks of treatment1*

NUCALA, 18% (n=12/68)
vs placebo, 3% (n=2/68)

Results are descriptive from secondary endpoint.

Decreased relapse rate

50%

dropdown

reduction in annualized
relapse rate1*§

NUCALA, 1.14 vs placebo, 2.27;
rate ratio: 0:50; 95% CI: 0.36, 0.70

Other endpoint. These results are descriptive
and not adjusted for multiplicity.

Pivotal trial design: 52-week, phase 3, randomized, placebo-controlled, double-blind study comparing 300 mg of NUCALA every 4 weeks plus standard of care (SOC) (n=68) vs placebo plus SOC (N=68); follow-up Weeks 52-60. Co-primary endpoints: NUCALA patients spent more time in remission over 52 weeks (OR: 5.9; 95% CI: 2.7, 13.0; P<0.001). More NUCALA patients were in remission at both Week 36 and Week 48 (OR: 16.7; 95% CI: 3.6, 77.6; P<0.001). Secondary endpoint: NUCALA patients achieved lower daily steroid dose during the last 4 weeks of treatment (OR: 0.20; 95% Cl: 0.09, 0.41).1

SOC was defined as OCS +/– immunosuppressants. After Week 4, OCS (prednisolone or prednisone) dose could be tapered, per physician judgment or a suggested protocol.

Remission was defined as Birmingham Vasculitis Activity Score (BVAS)=0 (no active vasculitis) plus OCS dose ≤4 mg/day.

Relapse was defined as a worsening related to vasculitis, asthma, or sinonasal symptoms requiring an increase in dose of corticosteroids, increase in dose or addition of immunosuppressive therapy, or hospitalization.

CI=confidence interval; OCS=oral corticosteroid; OR=odds ratio.

Patient check image

About EGPA

Description, clinical
manifestations, and more

Eosinophil reduction image

Eosinophil reduction
and mechanism of action (MOA)

See the results of NUCALA
on eosinophil reduction